Anti-androgen monotherapy for metastatic prostate cancer
Mené sur 62 patients atteints d'un cancer de la prostate et n'ayant pas encore reçu de traitement hormonal, cet essai de phase II évalue l'efficacité, du point de vue du pourcentage de patients pour lesquels le niveau de PSA a baissé de plus de 80% à 25 semaines, et la toxicité de l'enzalutamide en monothérapie
Prostate cancer is commonly an androgen-driven disease, and for several decades the mainstay of first-line treatment for metastatic disease has been medical or surgical castration to suppress gonadal androgens. The median time to progression on castration therapy for newly diagnosed patients presenting with metastatic disease is 12 months. 2 However, time to progression can vary greatly, with some patients responding to castration for several years...
The Lancet Oncology , commentaire, 2013